Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias

Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease

(2017) Susan H. Fox et al.   MOVEMENT DISORDERS

Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice

(2017) Xiomara A. Perez et al.   MOVEMENT DISORDERS

Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease

(2017) Ledia F. Hernández et al.   MOVEMENT DISORDERS

Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research

(2017) Nadhir Litim et al.   NEUROPHARMACOLOGY

A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA –Induced Dyskinesia and ∆FosB Expression

(2016) Michael Feyder et al.   BIOLOGICAL PSYCHIATRY

L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia

(2016) Luz M Suarez et al.   CEREBRAL CORTEX

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease

(2016) François Tison et al.   MOVEMENT DISORDERS

Antidyskinetic effect of A2Aand 5HT1A/1Breceptor ligands in two animal models of Parkinson's disease

(2016) Annalisa Pinna et al.   MOVEMENT DISORDERS

Hyperkinetic disorders and loss of synaptic downscaling

(2016) Paolo Calabresi et al.   NATURE NEUROSCIENCE

Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms

(2016) Veronica Ghiglieri et al.   NEUROBIOLOGY OF DISEASE

Serotonin-to-dopamine transporter ratios in Parkinson disease

(2016) Andreas-Antonios Roussakis et al.   NEUROLOGY

Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice

(2016) Roberta Marongiu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Derangement of Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Extracellular Signal-Regulated Kinase (ERK) Dependent Striatal Plasticity in L-DOPA-Induced Dyskinesia

(2015) Milica Cerovic et al.   BIOLOGICAL PSYCHIATRY

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study

(2015) Per Svenningsson et al.   BRAIN

NLX-112, a novel 5-HT 1A receptor agonist for the treatment of l -DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat

(2015) H. Iderberg et al.   EXPERIMENTAL NEUROLOGY

Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity

(2015) Giovanna Paolone et al.   MOVEMENT DISORDERS

Activity of serotonin 5-HT1A receptor ‘biased agonists’ in rat models of Parkinson's disease and l-DOPA-induced dyskinesia

(2015) H. Iderberg et al.   NEUROPHARMACOLOGY

Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson’s disease

(2015) C. Fidalgo et al.   NEUROSCIENCE

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

(2015) Matthieu F. Bastide et al.   PROGRESS IN NEUROBIOLOGY

NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients

(2015) Manuela Mellone et al.   Frontiers in Cellular Neuroscience

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients

(2014) Marios Politis et al.   JOURNAL OF CLINICAL INVESTIGATION

The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model

(2014) Erwan Bezard et al.   MOVEMENT DISORDERS

Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease

(2014) Wai Kin D. Ko et al.   MOVEMENT DISORDERS

Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia

(2014) I.A. Prescott et al.   NEUROBIOLOGY OF DISEASE

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias

(2014) Olivier Rascol et al.   PARKINSONISM & RELATED DISORDERS

L-DOPA Treatment Selectively Restores Spine Density in Dopamine Receptor D2–Expressing Projection Neurons in Dyskinetic Mice

(2013) Luz M. Suárez et al.   BIOLOGICAL PSYCHIATRY

Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: Effects of combined treatment and possible mechanisms of action

(2013) Hanna Iderberg et al.   EXPERIMENTAL NEUROLOGY

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study

(2013) Fabrizio Stocchi et al.   MOVEMENT DISORDERS

Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia

(2013) Erwan Bezard et al.   MOVEMENT DISORDERS

Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys

(2013) Nicolas Morin et al.   NEUROPHARMACOLOGY

Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia

(2013) Erwan Bézard et al.   NEUROSCIENCE RESEARCH

MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates

(2012) Nicolas Morin et al.   NEUROPHARMACOLOGY

Abnormal bidirectional plasticity-like effects in Parkinson's disease

(2011) Y.-Z. Huang et al.   BRAIN

Molecular basis of NMDA receptor functional diversity

(2011) Pierre Paoletti   EUROPEAN JOURNAL OF NEUROSCIENCE

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

(2011) Daniela Berg et al.   MOVEMENT DISORDERS

Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome

(2011) E. Lancaster et al.   NEUROLOGY

The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys

(2011) Laurent Grégoire et al.   PARKINSONISM & RELATED DISORDERS

Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia

(2010) Daniella Rylander et al.   ANNALS OF NEUROLOGY

Effect of l-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys

(2010) Bazoumana Ouattara et al.   JOURNAL OF NEUROCHEMISTRY

Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

(2010) T. H. Johnston et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia

(2010) Bai-Yun Zeng et al.   NEUROBIOLOGY OF DISEASE

Genetic Inactivation of Dopamine D1 but Not D2 Receptors Inhibits L-DOPA–Induced Dyskinesia and Histone Activation

(2009) Sanja Darmopil et al.   BIOLOGICAL PSYCHIATRY

Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model

(2009) Ana Muñoz et al.   EXPERIMENTAL NEUROLOGY

Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling

(2009) D. Rylander et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications

(2009) Bazoumana Ouattara et al.   NEUROBIOLOGY OF AGING

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia

(2008) A. Munoz et al.   BRAIN

Parkinson's disease: Levodopa-induced dyskinesia and signal transduction

(2008) Emanuela Santini et al.   FEBS Journal

Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats

(2008) Andreas Gravius et al.   JOURNAL OF NEURAL TRANSMISSION

l-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice

(2008) Emanuela Santini et al.   JOURNAL OF NEUROCHEMISTRY